Metalloenzyme inhibitor compounds
The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
1. A compound of formula (I), or salt, solvate, hydrate, or prodrug thereof:
wherein R 1 is optionally substituted naphthyl, R 2 is unsubstituted alkyl, and R 3 is H.
2. The compound of claim 1 , wherein R 1 is substituted naphthyl, R 2 is unsubstituted alkyl, and R 3 is H.
3. The compound of claim 2 , wherein R 1 is naphthyl substituted with 1, 2, 3 or 4 substituents, independently selected from alkyl, alkoxy, haloalkoxy, cyano, halo, amino, mono-alkylamino, di-alkylamino, or heteroaryl.
4. The compound of claim 1 , wherein R 2 is selected from the group consisting of methyl; ethyl; n-propyl; isopropyl; n-butyl; 2-butyl; isobutyl; tert-butyl; n-pentyl; 2-pentyl; 3-methyl-2-butyl; 3-pentyl; 2-methyl-3-butyl; 2-methyl-1-butyl; neopentyl; isopentyl; n-hexyl; 2-hexyl; 3-methyl-2-pentyl; 4-methyl-2-pentyl; 3-hexyl; 2-methyl-3-pentyl; 2,2-dimethyl-3-butyl; 2-methyl-1-pentyl; 2,3-dimethyl-1-butyl; 1,1-dimethyl-1-butyl; 1,1,2-trimethyl-1-propyl; 2,2-dimethyl-1-butyl; 2,2-dimethyl-3-butyl; 2,2-dimethyl-4-butyl; 2-ethyl-1-butyl; isohexyl; and 3-methyl-1-pentyl.
5. A compound having the structure of formula (III):
wherein X is CH;
Y is CH;
R 2 is optionally substituted aryl, optionally substituted naphthyl, optionally substituted heteroaryl, unsubstituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl-alkyl, or optionally substituted heteroaryl-(di)fluoroalkyl;
R 3 is H, optionally substituted alkyl, or optionally substituted cycloalkyl;
and R 4 and R 5 are independently H, halogen, alkoxy, fluoroalkoxy containing 1-5 fluorines, cyano, carboxamido, optionally substituted aryl, or optionally substituted heteroaryl.
6. The compound of claim 5 , wherein R 2 is selected from the group consisting of methyl; ethyl; n-propyl; isopropyl; n-butyl; 2-butyl; isobutyl; tert-butyl; n-pentyl; 2-pentyl; 3-methyl-2-butyl; 3-pentyl; 2-methyl-3-butyl; 2-methyl-1-butyl; neopentyl; isopentyl; n-hexyl; 2-hexyl; 3-methyl-2-pentyl; 4-methyl-2-pentyl; 3-hexyl; 2-methyl-3-pentyl; 2,2-dimethyl-3-butyl; 2-methyl-1-pentyl; 2,3-dimethyl-1-butyl; 1,1-dimethyl-1-butyl; 1,1,2-trimethyl-1-propyl; 2,2-dimethyl-1-butyl; 2,2-dimethyl-3-butyl; 2,2-dimethyl-4-butyl; 2-ethyl-1-butyl; isohexyl; and 3-methyl-1-pentyl.
7. A compound that is:
2-(1-(6,7-bis(difluoro methoxy)naphthalen-2-yl)-2-methylpropyl)-2H-tetrazole (1);
2-(2-Methyl-1-(6-(2,2,2-trifluoroethoxy)naphthalen-2-yl)propyl)-2H-tetrazole (2);
2-(1-(6,7-Dimethoxynaphthalen-2-yl)-2-methylpropyl)-2H-tetrazole (3);
2-(1-(6-(difluoromethoxy)naphthalen-2-yl)-2-methylpropyl)-2H-tetrazole (4);
or salt, solvate, hydrate or prodrug thereof.
8. A composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier.
9. The composition of claim 8 further comprising a therapeutic agent in addition to the compound of formula (III).
10. The composition of claim 8 further comprising a therapeutic agent in addition to the compound of formula (III), wherein the therapeutic agent is an anti-cancer agent, antifungal agent, cardiovascular agent, antiinflammatory agent, chemotherapeutic agent, an anti-angiogenesis agent, cytotoxic agent, an anti-proliferation agent, metabolic disease agent, opthalmologic disease agent, central nervous system (CNS) disease agent, urologic disease agent, or gastrointestinal disease agent.